iifl-logo

Sun Pharmaceuticals Industries Ltd Quarterly Results

1,690.6
(0.11%)
Jun 11, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2025Dec-2024Sept-2024Jun-2024Mar-2024

Gross Sales

12,815.58

13,436.94

13,264.22

12,524.51

11,813.33

Excise Duty

0

0

0

0

0

Net Sales

12,815.58

13,436.94

13,264.22

12,524.51

11,813.33

Other Operating Income

143.26

238.52

27.17

128.24

169.57

Other Income

612.87

465.62

354

532.55

605.94

Total Income

13,571.71

14,141.08

13,645.39

13,185.3

12,588.84

Total Expenditure

9,604.43

9,982.61

9,352.43

9,045.13

9,049.39

PBIDT

3,967.28

4,158.47

4,292.96

4,140.17

3,539.45

Interest

49.14

51.51

69.17

61.54

73.57

PBDT

3,918.14

4,106.96

4,223.79

4,078.63

3,465.88

Depreciation

663.79

630.56

625.91

655.13

650.36

Minority Interest Before NP

0

0

0

0

0

Tax

1,093.71

558.86

567.21

552.25

148.93

Deferred Tax

0

0

0

0

0

Reported Profit After Tax

2,160.64

2,917.54

3,030.67

2,871.25

2,666.59

Minority Interest After NP

4.05

9.6

-2.83

24.89

4.16

Net Profit after Minority Interest

2,149.88

2,903.38

3,040.16

2,835.62

2,654.58

Extra-ordinary Items

-240.13

-265.34

0

0

-96.26

Adjusted Profit After Extra-ordinary item

2,390.01

3,168.72

3,040.16

2,835.62

2,750.84

EPS (Unit Curr.)

9

12.1

12.7

11.8

11.1

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

1,050

0

0

0

Equity

239.93

239.93

239.93

239.93

239.93

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

30.95

30.94

32.36

33.05

29.96

PBDTM(%)

30.57

30.56

31.84

32.56

29.33

PATM(%)

16.85

21.71

22.84

22.92

22.57

Sun Pharma.Inds.: Related NEWS

Sun Pharma Expands Specialty Drug Pipeline with $25 Million Pharmazz Deal
24 May 2025|07:51 PM

Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.

Read More
Sun Pharma Q4 FY25 Revenue Rises 8.5% to ₹12,816 Crore
23 May 2025|12:07 PM

The Board recommended a final dividend of ₹5.50 per share for FY25.

Read More
Top Stocks for Today - 7th May 2025
7 May 2025|08:06 AM

NLC's subsidiary has executed a PPA with Rajasthan Rajya Vidyut Utpadan Nigam Ltd. (RVUNL) for 810 MW solar power plant at Pugal Solar Park, Rajasthan

Read More
Sun Pharma’s MM-II Trial Shows Long-Lasting Relief for Knee Osteoarthritis
26 Apr 2025|01:15 PM

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

Read More
Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million
10 Mar 2025|10:46 AM

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

Read More
Sun Pharma Q3 Profit Jumps 19% YoY, Declares ₹10.50 Dividend
31 Jan 2025|10:17 PM

An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.

Read More
Sun Pharma reports Q2 net profit at ₹3,040 Crore
29 Oct 2024|10:30 AM

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.

Read More
Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.